The effectiveness of the administration regimen of Вuserelin-depo with a prolonged interval between injections: hormonal profile and acceptability of treatment for patients with endometriosis
Rukhliada N.N.
Since gonadotropin releasing hormone (GnRH) agonists significantly suppress steroidogenesis, they contribute to the regression of endometrioid lesions and the decrease in clinical symptoms of the disease. However, hypoestrogenism caused by the prolonged use of GnRH agonists is complicated by the appearance of side effects. It is important to find the ways to reduce side effects while maintaining the effectiveness of GnRH agonists. Objective: To assess the clinical and hormonal status of patients with extragenital endometriosis after taking 3.75 mg of Buserelin-depo with 6-week and 4-week intervals between the administration of the drug in the postoperative period. Materials and methods: The patients of group I (n=10) were administered Buserelin-depo at a standard dose of 3.75 mg with an interval of 6 weeks; the patients of group II (n=10) who had ASRM stage I and II verified endometriosis were administered the drug according to the usual scheme with a 4-week interval. The study included the comparison of the dynamics of estradiol, LH, FSH, the rate of appearance and the profile of side effects associated with induced hypoestrogenism, the clinical efficacy of drug administration in both groups. Results: The levels of FSH, LH and E2 in patients of both groups showed similar results of hormonal suppression. A decrease in pain syndrome was also observed after the administration of Buserelin-depo: 3.3 scores using the VAS system in group I and 2.4 scores in group II (compared to 9.9 points initially). Menstruation started again in 78 days after the fourth injection in group I and in 82 days after the sixth injection in group II. In both groups, adverse events were noted which were mild according to the Kupperman index (in 6/10 in group I, in 10/10 in group II). Neither endometrial growth nor signs of folliculogenesis were observed in any case in groups I and II. Conclusion: The effectiveness of the administration of Buserelin-depo with an increased interval between injections for up to 6 weeks is equal to the effectiveness of its administration in the standard mode (every 4 weeks). However, the side effects were less severe. It is necessary to conduct a comprehensive study in order to clarify the effectiveness of the prolonged interval between injections using statistical analysis.
Conflicts of interests: The author declares no conflict of interest.
Funding: The study was conducted without sponsorship.
Ethical Approval: The study was approved by the Ethical Review Board of the Saint Petersburg State Pediatric Medical University, Ministry of Health of Russia.
Patient Consent for Publication: The patients signed an informed consent for the publication of their data.
Authors' Data Sharing Statement: The data supporting the findings of this study are available on request from the corresponding author after approval from the principal investigator.
For citation: Rukhliada N.N. The effectiveness of the administration regimen of Buserelin-depo with a prolonged interval between injections: hormonal profile and acceptability of treatment for patients with endometriosis. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2023; (10): 153-158 (in Russian) https://dx.doi.org/10.18565/aig.2023.245
Keywords
endometriosis
gonadotropin releasing hormone
Buserelin-depo
follicle stimulating hormone
luteinizing hormone
17β-estradiol
pelvic pain
References
- Адамян Л.В., Арсланян К.Н., Харченко Э.И., Логинова О.Н. Современные направления в медикаментозном лечении эндометриоза. Проблемы репродукции. 2019; 25(6): 58 66. [Adamyan L.V., Arslanyan K.N., Kharchenko E.I., Loginova O.N. Modern trends in the treatment of endometriosis. Russian Journal of Human Reproduction. 2019; 25(6): 58 66. (in Russian)]. https://dx.doi.org/10.17116/repro20192506158.
- Рухляда Н.Н., Бирюкова Е.И. Особенности фармакокинетики и биологические эффекты агонистов гонадотропин-рилизинг-гормона. Акушерство и гинекология. 2023; 2: 154-8. [Rukhlyada N.N., Biryukova E.I. The characteristics of pharmacokinetics and the biological effects of gonadotropin-releasing hormone agonists. Obstetrics and Gynecology. 2023; (2): 154-8. (in Russian)]. https://dx.doi.org/10.18565/aig.2023.42.
- Сапрыкина Л.В., Доброхотова Ю.Э., Сапрыкина О.А. Эндометриоз: гормональная терапия с позиций патогенеза. Эффективная фармакотерапия. Акушерство и гинекология. 2015; 25(3): 42-7. [Saprykina L.V., Dobrokhotova Yu.E., Saprykina O.A. Endometriosis: a pathogenetically justified hormone therapy. Effective Pharmacotherapy. Obstetrics and Gynecology. 2015; 25(3): 42-7. (in Russian)].
- Ховрина Е.А., Кирпиков А.С., Кузнецова И.В. Терапия прикрытия в лечении эндометриоза агонистами гонадотропин-рилизинг-гормона. Акушерство и гинекология. 2011; 4: 134-9. [Khovrina E.A., Kirpikov A.S., Kuznetsova I.V. Escort therapy in gonadotropin-releasing hormone agonist treatment for endometriosis. Obstetrics and Gynecology. 2011; (4): 134-9. (in Russian)].
- Bazybek N., Wei Y., Ma G. Advances in encapsulating gonadotropin-releasing hormone agonists for controlled release: a review. J. Microencapsul. 2022; 39(5): 452-66. https://dx.doi.org/10.1080/02652048.2022.2100934.
- Broekmans F.J., Bernardus R.E., Berkhout G., Schoemaker J. Pituitary and ovarian suppression after early follicular and mid-luteal administration of a LHRH agonist in a depot formulation: decapeptyl CR. Gynecol. Endocrinol. 1992; 6(3): 153-61. https://dx.doi.org/10.3109/09513599209015549.
- Качалина Т.С., Зиновьев А.Н., Зяблова М.Е. Рецидивы эндометриоидных кист: факторы риска и профилактика. Эффективная фармакотерапия. Акушерство и гинекология. 2016; 14(1-2): 6-10. [Kachalina T.S., Zinovyev A.N., Zyablova M.Ye. Relapsing endometrial cysts: risk factors and prevention. Effective Pharmacotherapy. Obstetrics and Gynecology. 2016; 14(1-2): 6-10. (in Russian)].
- Chiu C.C., Hsu T.F., Jiang L.Y., Chan I.S., Shih Y.C., Chang Y.H. et al. Maintenance therapy for preventing endometrioma recurrence after endometriosis resection surgery - a systematic review and network meta-analysis. J. Minim. Invasive Gynecol. 2022; 29(5): 602-12. https://dx.doi.org/10.1016/j.jmig.2021.11.024.
- Zhang K., Huang S., Xu H., Zhang J., Wang E., Li Y. et al. Effectiveness of gonadotrophin-releasing hormone agonist therapy to improve the outcomes of intrauterine insemination in patients suffering from stage I-II endometriosis. Ann. Med. 2022; 54(1): 1330-8. https://dx.doi.org/10.1080/07853890.2022.2071458.
- Liu D., Gu M., Shu J., Shi Y., Wang C., Han Z. [Effect of triptorelin and an extended-interval dosing regimen in the treatment of patients with endometriosis and adenomyoma]. Zhonghua Fu Chan Ke Za Zhi. 2006; 41(10): 656-9. in Chinese.
- Yang Y., Zhu W., Chen S., Zhang G., Chen M., Zhuang Y. Laparoscopic Surgery Combined with GnRH agonist in endometriosis. J. Coll. Physicians Surg. Pak. 2019; 29(4): 313-6. https://dx.doi.org/10.29271/jcpsp.2019.04.313.
- Ярмолинская М.И., Денисова В.М. Современные подходы к назначению add-back-терапии больным генитальным эндометриозом. Эффективная фармакотерапия. Акушерство и гинекология. 2015; 36(4): 24-31. [Yarmolinskaya M.I., Denisova V.M. Modern approaches to add-back therapy in patients with genital endometriosis. Effective Pharmacotherapy. Obstetrics and Gynecology. 2015; 36(4): 24-31. (in Russian)].
- Cheung T.K., Lo K.W., Lam C.W., Lau W., Lam P.K. A crossover study of triptorelin and leuprorelin acetate. Fertil. Steril. 2000; 74(2): 299-305. https://dx.doi.org/10.1016/s0015-0282(00)00598-7.
- Vercellini P., Bandini V., Buggio L., Barbara G., Berlanda N., Dridi D. et al. Mitigating the economic burden of GnRH agonist therapy for progestogen-resistant endometriosis: why not? Hum. Reprod. Open. 2023; 2023(2): hoad008. https://dx.doi.org/10.1093/hropen/hoad008.
- Resta C., Moustogiannis A., Chatzinikita E., Ntalianis D.M., Ntalianis K.M., Philippou A. et al. Gonadotropin-releasing hormone (GnRH)/GnRH receptors and their role in the treatment of endometriosis. Cureus. 2023; 15(4): e38136. https://dx.doi.org/10.7759/cureus.38136.
- Surrey E.S. GnRH agonists in the treatment of symptomatic endometriosis: a review. F S Rep. 2022; 4(2,Suppl.): 40-5. https://dx.doi.org/10.1016/j.xfre.2022.11.009.
- Gong L., Zhang S., Han Y., Long Q., Zou S., Cao Y. Initiation of GnRH agonist treatment on 3-5 days postoperatively in endometriosis patients: a randomized controlled trial. J. Clin. Pharmacol. 2015; 55(8): 848-53. https://dx.doi.org/10.1002/jcph.485.
- Kang J., Wang X., Nie M., Huang X. Efficacy of gonadotropin-releasing hormone agonist and an extended-interval dosing regimen in the treatment of patients with adenomyosis and endometriosis. Gynecol. Obstet. Invest. 2010; 69(2): 73-7. https://dx.doi.org/10.1159/000258683.
- Matteo M., Caroppo E., Gliozheni O., Carone D., Schonauer L.M., Vizziello G. et al. Pituitary desensitization for eight weeks after the administration of two distinct gonadotrophin-releasing hormone agonists. Eur. J. Obstet. Gynecol. Reprod. Biol. 2006; 126(1): 77-80. https://dx.doi.org/10.1016/j.ejogrb.2005.09.018.
Received 23.10.2022
Accepted 27.10.2023
About the Authors
Nikolai N. Rukhliada, Dr. Med. Sci., Professor, Head of the Department of Obstetrics and Gynecology, St. Petersburg State Pediatric Medical University,Ministry of Health of Russia, +7(911)913-20-20, nickolasr@mail.ru, https://orcid.org/0000-0002-3548-0468, 194100, Russia, St. Petersburg, Litovskaya str., 2.
Similar Articles
